(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 September 2021 (10.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/178725 A1

(51) International Patent Classification:
A61K 9/10 (2006.01) *B82Y 5/00* (2011.01)
A61K 9/127 (2006.01)

(21) International Application Number:
PCT/US2021/020955

(22) International Filing Date:
04 March 2021 (04.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/984,866 04 March 2020 (04.03.2020) US
63/078,982 16 September 2020 (16.09.2020) US

(71) Applicant: **VERVE THERAPEUTICS, INC.** [US/US]; 500 Technology Square, Suite 901, Cambridge, MA 02139 (US).

(72) Inventors: **RAJEEV, Kallanthottathil, G.**; 500 Technology Square, Suite 901, Cambridge, MA 02139 (US). **BISWAS, Souvik**; 500 Technology Square, Suite 901, Cambridge, MA 02139 (US). **MALYALA, Padma**; 500 Technology Square, Suite 901, Cambridge, MA 02139 (US). **KASIEWICZ, Lisa, N.**; 500 Technology Square, Suite 901, Cambridge, MA 02139 (US). **CHADWICK, Alexandra**; 500 Technology Square, Suite 901, Cambridge, MA 02139 (US). **REISS, Caroline**; 500 Technology Square, Suite 901, Cambridge, MA 02139 (US).

(74) Agent: **CHEN, Ying**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

(54) Title: COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY




FIG. 15

(57) Abstract: Provided herein are compositions, methods of making the same, and methods for targeted delivery of therapeutic agents for modifying expression and function of target genes, e.g. proteins involved in lipid and cholesterol metabolism such as PCSK9. Further provided herein are compositions and methods of treating conditions related to coronary disease.

WO 2021/178725 A1

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*